CONCORD, Mass., Aug. 23, 2023 /PRNewswire/ — Comanche Biopharma Corp. today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. CBP-4888 is a…
Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia
This post was originally published on this site